Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Institut fur Allergieforschung Charite - Universitatsmedizin Berlin, Berlin

Allergy and Clinical Immunology Associates, Pittsburgh

Johns Hopkins University, Baltimore

National Allergy and Asthma Research, LLC., North Charleston

Medizinische Hochschule Hannover, Hanover

Advanced Clinical Research Institute, Tampa

Allergy & Asthma Specialists, P.S.C., Owensboro

Bernstein Clinical Research Center, LLC, Cincinnati

Hospital Arnau de Vilanova, Valencia

Treasure Valley Medical Research, Boise

Innovaderm Research Inc., Montreal

Gordon Sussman Clinical Research Inc., North York

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden

Centre for Human Drug Research (CHDR), Leiden

Hospital del Mar, Barcelona